guest ::
| Home > Publications database > Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies. > print |
| Home > Publications database > Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies. > print |
| 001 | 290075 | ||
| 005 | 20250731110223.0 | ||
| 024 | 7 | _ | |a 10.1002/ijc.34988 |2 doi |
| 024 | 7 | _ | |a pmid:38721724 |2 pmid |
| 024 | 7 | _ | |a 0020-7136 |2 ISSN |
| 024 | 7 | _ | |a 1097-0215 |2 ISSN |
| 024 | 7 | _ | |a altmetric:163339697 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00974 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Janssen, Maike |0 0000-0001-9899-1022 |b 0 |
| 245 | _ | _ | |a Treatment of chronic COVID-19 with convalescent/postvaccination plasma in patients with hematologic malignancies. |
| 260 | _ | _ | |a Bognor Regis |c 2024 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726657227_11602 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Aug 15;155(4):618-626 |
| 520 | _ | _ | |a Immunocompromised patients are at high risk to fail clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a health risk and a management problem as cancer treatments often have to be disrupted. As SARS-CoV-2 evolves, new variants of concern have emerged that evade available monoclonal antibodies. Moreover, antiviral therapy promotes SARS-CoV-2 escape mutations, particularly in immunocompromised patients. These patients frequently suffer from prolonged infection. No successful treatment has been established for persistent COVID-19 infection. Here, we report on a series of 21 immunocompromised patients with COVID-19-most of them hematologic malignancies-treated with plasma obtained from recently convalescent or vaccinated donors or a combination thereof. Repeated dosing of SARS-CoV-2-antibody-containing plasma could clear SARS-CoV-2 infection in 16 out of 21 immunocompromised patients even if COVID-19-specific treatments failed to induce sustained viral clearance or to improve clinical course of SARS-CoV-2 infection. Ten patients were major responders defined as an increase delta(d)Ct of > = 5 after the first administration of convalescent and/or vaccinated plasma (C/VP). On average, SARS-CoV-2 PCR Ct values increased from a median value of 22.55 (IQR = 19.10-24.25) to a median value of 29.57 (IQR = 27.55-34.63; p = <.0001) in the major response subgroup. Furthermore, when treated a second time with C/VP, even 4 out of 5 of the initial nonresponders showed an increase in Ct-values from a median value of 23.13 (IQR = 17.75-28.05) to a median value of 32.79 (IQR = 31.75-33.75; p = .013). Our results suggest that C/VP could be a feasible treatment of COVID-19 infection in patients with hematologic malignancies who did not respond to antiviral treatment. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a COVID‐19 |2 Other |
| 650 | _ | 7 | |a SARS‐CoV‐2‐antibody containing plasma |2 Other |
| 650 | _ | 7 | |a prolonged SARS‐CoV‐2 infection |2 Other |
| 700 | 1 | _ | |a Leo, Albrecht |b 1 |
| 700 | 1 | _ | |a Wolf, Cornelia |b 2 |
| 700 | 1 | _ | |a Stenzinger, Miriam |b 3 |
| 700 | 1 | _ | |a Bartenschlager, Marie |b 4 |
| 700 | 1 | _ | |a Brandt, Juliane |b 5 |
| 700 | 1 | _ | |a Sauer, Sandra |b 6 |
| 700 | 1 | _ | |a Schmitt, Michael |b 7 |
| 700 | 1 | _ | |a Dreger, Peter |b 8 |
| 700 | 1 | _ | |a Schlenk, Richard F |0 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |b 9 |u dkfz |
| 700 | 1 | _ | |a Denkinger, Claudia M |b 10 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |0 P:(DE-HGF)0 |b 11 |
| 773 | _ | _ | |a 10.1002/ijc.34988 |g p. ijc.34988 |0 PERI:(DE-600)1474822-8 |n 4 |p 618-626 |t International journal of cancer |v 155 |y 2024 |x 0020-7136 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290075/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janssen%20-%20Treatment%20of%20chronic%20COVID%E2%80%9019%20with%20convalescent%20postvaccination%20plasma%20in.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/290075/files/Intl%20Journal%20of%20Cancer%20-%202024%20-%20Janssen%20-%20Treatment%20of%20chronic%20COVID%E2%80%9019%20with%20convalescent%20postvaccination%20plasma%20in.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:290075 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b INT J CANCER : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)W010-20160331 |k W010 |l Klinische Studienzentrale |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)W010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|